RARE
Ultragenyx Pharmaceutical Inc.
$29.96
-$0.34(-1.12%)
38
Overall
--
Value
27
Tech
50
Quality
Market Cap
$2.85B
Volume
1.34M
52W Range
$25.81 - $60.37
Target Price
$85.85
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | $133.0K | $2.6M | $51.5M | $103.7M | $271.0M | $351.4M | $363.3M | $434.2M | $560.2M | ||
| Total Revenue | -- | $133.0K | $2.6M | $51.5M | $103.7M | $271.0M | $351.4M | $363.3M | $434.2M | $560.2M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | $-1.0K | $-1.1M | -- | $6.1M | $16.0M | $28.3M | $45.2M | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | $133.0K | $2.6M | $51.5M | $103.7M | $264.9M | $335.4M | $335.0M | $434.2M | $560.2M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-147.7M | $-248.1M | $-331.6M | $-422.9M | $527.9M | $588.9M | $701.1M | $983.9M | $958.2M | $1.0B | ||
| Research & Development | $114.7M | $183.2M | $231.6M | $294.0M | $357.4M | $412.1M | $497.2M | $705.8M | $648.4M | $697.9M | ||
| Research Expense | $114.7M | $183.2M | $231.6M | $294.0M | $357.4M | $412.1M | $497.2M | $705.8M | $648.4M | $697.9M | ||
| Selling, General & Administrative | $33.0M | $64.9M | $99.9M | $127.7M | $161.5M | $182.9M | $220.0M | $278.1M | $309.8M | $321.6M | ||
| Selling & Marketing Expenses | -- | $64.9M | $99.9M | $127.7M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $33.0M | $-3.3M | $-4.5M | $-6.4M | $161.5M | $182.9M | $220.0M | $278.1M | $309.8M | $321.6M | ||
| Salaries & Wages | $-24.9M | $-48.3M | $-68.0M | $-80.1M | -- | $-6.1M | $-16.0M | -- | -- | -- | ||
| Depreciation & Amortization | $-1.4M | $-3.4M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-1.4M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | -- | $44.4M | $158.0K | $131.1M | $160.4M | $166.5M | $178.3M | ||
| Other Operating Expenses | $-147.7M | $-248.1M | $-331.6M | $1.1M | $-9.0M | $-7.0M | $-8.5M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-147.7M | $-248.0M | $-328.9M | $-371.4M | $-424.2M | $-330.1M | $-381.7M | $-648.9M | $-569.2M | $-536.0M | ||
| EBITDA | $-138.6M | $-237.6M | $-310.8M | $-180.2M | $-397.1M | $-139.8M | $-410.3M | $-640.5M | $-582.5M | $-532.0M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | $33.3M | $29.4M | $43.0M | $66.0M | -- | ||
| Intinc | $2.3M | $3.8M | $4.1M | $9.5M | $13.2M | $7.0M | $1.9M | $11.1M | $26.7M | $36.5M | ||
| Net Non-Operating Interest Income/Expense | $2.3M | $3.8M | $4.1M | $9.5M | $13.2M | $7.0M | $1.9M | $31.9M | $26.7M | $36.5M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | $13.4M | $170.4M | $-42.1M | $-19.3M | $397.0K | $-1.1M | ||
| Other Income/Expense | $200.0K | $1.6M | $-6.5M | $-164.7M | $-12.6M | $-171.0M | $43.8M | $-20.9M | $-60.0K | $5.1M | ||
| Other Special Charges | $-200.0K | $-1.6M | $6.5M | $-5.6M | $-787.0K | $607.0K | $-1.7M | $-1.6M | $-337.0K | $-4.0M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | $-306.6M | $-341.7M | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | -- | $306.6M | $341.7M | -- | -- | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-145.6M | $-245.8M | $-318.3M | $-197.1M | $-399.4M | $-152.1M | $-423.6M | $-658.7M | $-608.5M | $-567.6M | ||
| Pre-Tax Income | $-145.6M | $-245.8M | $-318.3M | $-197.1M | $-399.4M | $-185.4M | $-453.0M | $-701.7M | $-608.5M | $-567.6M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $35.0K | $-16.2M | $514.0K | $3.3M | $1.2M | $1.0M | $5.7M | $-1.8M | $1.6M | ||
| NET INCOME | ||||||||||||
| Net Income | $-145.6M | $-245.9M | $-302.1M | $-197.6M | $-402.7M | $-186.6M | $-454.0M | $-707.4M | $-606.6M | $-569.2M | ||
| Net Income (Continuing Operations) | $-145.6M | $-245.9M | $-302.1M | $-197.6M | $-402.7M | $-186.6M | $-454.0M | $-707.4M | $-606.6M | $-569.2M | ||
| Net Income (Discontinued Operations) | $-145.6M | $-245.9M | $-302.1M | $-197.6M | $-402.7M | $-186.6M | $-454.0M | $-707.4M | $-606.6M | $-569.2M | ||
| Net Income (Common Stockholders) | $-145.6M | $-245.9M | $-302.1M | $-197.6M | $-383.6M | $-186.6M | $-454.0M | $-707.4M | $-606.6M | $-569.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-147.7M | $-248.1M | $-331.6M | $-422.9M | $527.9M | $588.9M | $701.1M | $1.0B | $958.2M | $1.0B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $36.8M | $39.6M | $42.5M | $49.8M | $56.6M | $60.8M | $67.8M | $69.9M | $73.5M | $90.5M | ||
| Average Shares Outstanding (Diluted) | $36.8M | $39.6M | $42.4M | $49.8M | $56.6M | $60.8M | -- | $69.9M | $73.5M | $90.5M | ||
| Shares Outstanding | $39.0M | $41.7M | $49.6M | $51.3M | $57.9M | $66.9M | $69.4M | $70.2M | $82.3M | $92.5M | ||
| Basic EPS | -- | -- | -- | $-1.73 | $-7.12 | $-3.07 | $-6.7 | $-10.12 | $-8.25 | $-6.29 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-7.12 | $-3.07 | $-6.7 | $-10.12 | $-8.25 | $-6.29 | ||
| Diluted EPS | $-3.96 | $-6.21 | $-7.12 | $-3.97 | $-7.12 | $-3.07 | $-6.7 | $-10.12 | $-8.25 | $-6.29 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-10.12 | $-8.25 | $-6.29 | ||
| Dividend Per Share | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | -- | -- | -- | $170.3M | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $33.0M | $-3.3M | $-4.5M | $-6.4M | $161.5M | $182.9M | $220.0M | $278.1M | $309.8M | $321.6M | ||
| Rent And Landing Fees | $33.0M | $-3.3M | $-4.5M | $-6.4M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | $64.9M | $99.9M | $127.7M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | $-306.6M | $-341.7M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RARE | $29.96 | -1.1% | 1.34M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ultragenyx Pharmaceutical Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW